World's Best Scientists 2026 revealed!
Jean-Michel Molina

Jean-Michel Molina

D-Index & Metrics

Microbiology

D-Index
97
Citations
38420
World Ranking
475
National Ranking
26

Best Publications

  • HLA-B*5701 Screening for Hypersensitivity to Abacavir

    Simon Mallal;Elizabeth Phillips;Giampiero Carosi;Jean-Michel Molina

  • On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

    Abstr Act;C. Capitant;B. Spire;G. Pialoux

  • No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.

    J.M. Molina;C. Delaugerre;J. Le Goff;B. Mela-Lima

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

    Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  • Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

    Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Hematopoietic growth factors. Biology and clinical applications.

    J E Groopman;J M Molina;D T Scadden

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

    Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  • Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus

    Alexandre Karras;Matthieu Lafaurie;André Furco;Anne Bourgarit

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

    Michael S. Saag;Rajesh T. Gandhi;Jennifer F. Hoy;Raphael J. Landovitz

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

    Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina

  • Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment

    Yves Levy;Christine Lacabaratz;Laurence Weiss;Jean-Paul Viard

  • Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  • Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

    Jean-Michel Molina;Isabelle Charreau;Christian Chidiac;Gilles Pialoux

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS

    Emmanuelle Boulanger;Laurence Gérard;Jean Gabarre;Jean-Michel Molina

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Jean-Michel Molina

Recently Published Articles